FDA Approves Gilead's Bixlenvo, a Once-Daily Single Tablet for Suppressed HIV
GILD sits 37% above its 52-week low of $108.46.
Summary
The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV, including those on complex regimens. This expands Gilead's HIV portfolio with a convenient option that could capture share from multi-pill regimens. The approval follows a strong Q2 and recent Trodelvy label expansions, reinforcing Gilead's pipeline momentum. Watch for launch pricing and payer coverage decisions in the coming quarters.
At the time of this announcement, GILD was trading at $148.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.6B. The 52-week trading range was $108.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.